MX351582B - Inhibidores de pde9 con estructura basica de imidazotriazinona. - Google Patents
Inhibidores de pde9 con estructura basica de imidazotriazinona.Info
- Publication number
- MX351582B MX351582B MX2014008912A MX2014008912A MX351582B MX 351582 B MX351582 B MX 351582B MX 2014008912 A MX2014008912 A MX 2014008912A MX 2014008912 A MX2014008912 A MX 2014008912A MX 351582 B MX351582 B MX 351582B
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- formula
- effective amount
- therapeutically effective
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a compuestos, que son inhibidores de la enzima PDE9. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de la invención y un portador farmacéuticamente aceptable. La presente invención también proporciona procesos para preparar compuestos de fórmula (I). La presente invención proporciona además un método para tratar un sujeto que padece un trastorno neurodegenerativo que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula (I). La presente invención proporciona además un compuesto de fórmula (I) para su uso en un método para tratar un sujeto que padece un trastorno psiquiátrico que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de fórmula (I). (ver Fórmula).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012070718 | 2012-01-26 | ||
CN2012080208 | 2012-08-16 | ||
PCT/EP2013/051451 WO2013110768A1 (en) | 2012-01-26 | 2013-01-25 | Pde9 inhibitors with imidazo triazinone backbone |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014008912A MX2014008912A (es) | 2014-08-26 |
MX351582B true MX351582B (es) | 2017-10-20 |
Family
ID=47603775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008912A MX351582B (es) | 2012-01-26 | 2013-01-25 | Inhibidores de pde9 con estructura basica de imidazotriazinona. |
Country Status (15)
Country | Link |
---|---|
US (3) | US9434733B2 (es) |
EP (2) | EP2807163B1 (es) |
CN (2) | CN104093720B (es) |
AP (1) | AP2014007820A0 (es) |
AU (2) | AU2013213603B2 (es) |
BR (1) | BR112014018199A8 (es) |
CO (1) | CO7020913A2 (es) |
CR (1) | CR20140361A (es) |
DO (1) | DOP2014000175A (es) |
EC (1) | ECSP14015609A (es) |
HK (1) | HK1199879A1 (es) |
MX (1) | MX351582B (es) |
PH (1) | PH12014501695B1 (es) |
SG (1) | SG11201403909RA (es) |
WO (1) | WO2013110768A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR083058A1 (es) | 2010-09-20 | 2013-01-30 | Envivo Pharmaceuticals Inc | Compuestos de estructura de imidazotriazinona |
WO2012047121A1 (en) | 2010-10-08 | 2012-04-12 | Fisher & Paykel Healthcare Limited | Breathing assistance apparatus |
EP2906562B1 (en) | 2011-10-10 | 2016-10-05 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
CN104093720B (zh) * | 2012-01-26 | 2017-04-12 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
EP2828262A4 (en) * | 2012-03-19 | 2015-09-23 | Forum Pharmaceuticals Inc | IMIDAZOTRIAZINONVERBINDUNGEN |
KR20160007347A (ko) | 2014-07-11 | 2016-01-20 | 에스티팜 주식회사 | 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도 |
WO2016006975A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
SI3865484T1 (sl) | 2015-07-07 | 2024-05-31 | H. Lundbeck A/S | Zaviralec pde9 z imidazo pirazinonsko hrbtenico za zdravljenje perifernih bolezni |
CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
BR112019000005A2 (pt) * | 2016-07-06 | 2019-04-16 | H. Lundbeck A/S | inibidores de pde9 para o tratamento de doenças periféricas |
EP3529250B1 (en) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
MA46611B1 (fr) | 2016-10-28 | 2020-08-31 | H Lundbeck As | Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs |
CA3041595A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
PT3541784T (pt) * | 2016-11-18 | 2023-11-22 | Integrative Res Laboratories Sweden Ab | Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical |
KR102643197B1 (ko) * | 2017-02-23 | 2024-03-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 화합물 iii의 새로운 의학 용도 |
TWI843393B (zh) | 2017-05-26 | 2024-05-21 | 美商卡杜隆製藥公司 | 製備和使用pde9抑制劑之方法 |
CN110003213B (zh) * | 2018-01-04 | 2021-10-08 | 南京农业大学 | 苯并咪唑并三嗪酮类化合物、制备方法及应用 |
MX2020007066A (es) | 2018-01-05 | 2020-09-09 | Dicerna Pharmaceuticals Inc | Reduccion de la expresion de beta-catenina e ido para potenciar la inmunoterapia. |
BR112020024019A2 (pt) | 2018-05-25 | 2021-02-23 | Imara Inc. | monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona |
EP3965768A1 (en) * | 2019-05-07 | 2022-03-16 | Imara Inc. | Pde9 inhibitors for treating thalassemia |
CN113072556B (zh) * | 2021-03-30 | 2022-02-01 | 牡丹江医学院 | 一种用于治疗胶质瘤的药物及其制备方法 |
WO2024107445A1 (en) * | 2022-11-15 | 2024-05-23 | Freedom Biosciences, Inc. | Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterases |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23063A3 (es) | 1997-11-12 | 2005-07-19 | Bayer Ag | Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas |
SK10322001A3 (sk) | 1999-01-20 | 2002-07-02 | Arzneimittelwerk Dresden Gmbh | Spôsob prípravy imidazo [1,5-a]pyrido[3,2-e]pyrazínov, farmaceutické prostriedky obsahujúce takéto zlúčeniny a spôsob výroby farmaceutického prostriedku |
KR20040053210A (ko) * | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Pde9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
GB2388111A (en) | 2002-05-01 | 2003-11-05 | Bayer Ag | Novel imidazotriazinone compounds |
US6684626B1 (en) | 2002-07-30 | 2004-02-03 | General Electric Company | Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines |
US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
BRPI0416118A (pt) | 2003-10-31 | 2007-01-02 | Pfizer Prod Inc | inibição da fosfodiesterase 9 como tratamento para estados relacionados com a obesidade |
AR053090A1 (es) | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
US8299080B2 (en) | 2006-12-13 | 2012-10-30 | Aska Pharmaceutical Co., Ltd. | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor |
RS52166B (en) * | 2007-05-11 | 2012-08-31 | Pfizer Inc. | AMINO-HETEROCYCLIC COMPOUNDS |
DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
EA201070725A1 (ru) | 2007-12-10 | 2011-02-28 | Глэксо Груп Лимитед | Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
US20110082147A1 (en) | 2009-07-24 | 2011-04-07 | Concert Pharmaceuticals, Inc. | Substituted imidazotriazines |
US9260432B2 (en) | 2009-09-02 | 2016-02-16 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
AR083058A1 (es) * | 2010-09-20 | 2013-01-30 | Envivo Pharmaceuticals Inc | Compuestos de estructura de imidazotriazinona |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
CN104093720B (zh) | 2012-01-26 | 2017-04-12 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
-
2013
- 2013-01-25 CN CN201380006255.2A patent/CN104093720B/zh active Active
- 2013-01-25 US US14/374,278 patent/US9434733B2/en active Active
- 2013-01-25 AU AU2013213603A patent/AU2013213603B2/en active Active
- 2013-01-25 AP AP2014007820A patent/AP2014007820A0/xx unknown
- 2013-01-25 EP EP13701270.4A patent/EP2807163B1/en active Active
- 2013-01-25 EP EP17152165.1A patent/EP3178820B1/en active Active
- 2013-01-25 CN CN201710176546.6A patent/CN107082783B/zh active Active
- 2013-01-25 SG SG11201403909RA patent/SG11201403909RA/en unknown
- 2013-01-25 WO PCT/EP2013/051451 patent/WO2013110768A1/en active Application Filing
- 2013-01-25 BR BR112014018199A patent/BR112014018199A8/pt active Search and Examination
- 2013-01-25 MX MX2014008912A patent/MX351582B/es active IP Right Grant
-
2014
- 2014-07-24 CO CO14161415A patent/CO7020913A2/es unknown
- 2014-07-24 CR CR20140361A patent/CR20140361A/es unknown
- 2014-07-25 PH PH12014501695A patent/PH12014501695B1/en unknown
- 2014-07-25 DO DO2014000175A patent/DOP2014000175A/es unknown
- 2014-08-25 EC ECIEPI201415609A patent/ECSP14015609A/es unknown
-
2015
- 2015-01-13 HK HK15100346.4A patent/HK1199879A1/xx unknown
-
2016
- 2016-04-04 US US15/089,819 patent/US9533992B2/en active Active
- 2016-11-22 US US15/358,168 patent/US9850249B2/en active Active - Reinstated
-
2017
- 2017-02-09 AU AU2017200886A patent/AU2017200886B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CR20140361A (es) | 2014-11-11 |
DOP2014000175A (es) | 2014-08-31 |
EP3178820A1 (en) | 2017-06-14 |
AU2017200886A1 (en) | 2017-03-02 |
CN107082783B (zh) | 2019-03-22 |
AU2017200886B2 (en) | 2018-01-18 |
HK1199879A1 (en) | 2015-07-24 |
SG11201403909RA (en) | 2014-10-30 |
AP2014007820A0 (en) | 2014-07-31 |
PH12014501695A1 (en) | 2014-10-20 |
WO2013110768A1 (en) | 2013-08-01 |
US9434733B2 (en) | 2016-09-06 |
US9533992B2 (en) | 2017-01-03 |
CO7020913A2 (es) | 2014-08-11 |
US9850249B2 (en) | 2017-12-26 |
CN104093720B (zh) | 2017-04-12 |
CN107082783A (zh) | 2017-08-22 |
US20150045348A1 (en) | 2015-02-12 |
EP3178820B1 (en) | 2017-12-20 |
EP2807163A1 (en) | 2014-12-03 |
US20170081333A1 (en) | 2017-03-23 |
AU2013213603A1 (en) | 2014-07-24 |
ECSP14015609A (es) | 2015-12-31 |
MX2014008912A (es) | 2014-08-26 |
EP2807163B1 (en) | 2017-03-22 |
PH12014501695B1 (en) | 2014-10-20 |
US20160213674A1 (en) | 2016-07-28 |
BR112014018199A8 (pt) | 2021-03-02 |
CN104093720A (zh) | 2014-10-08 |
AU2013213603B2 (en) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014501695A1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
TN2015000100A1 (en) | Pde9i with imidazo pyrazinone backbone | |
MY152949A (en) | Novel phenylimidazole derivatives as pde10a enzyme inhibitors | |
MY158202A (en) | 2-arylimidazole derivatives as pde10a anzyme inhibitors | |
JO3089B1 (ar) | مشتقات ايميدازول كمثبطات لانزيمات pde10a | |
TN2012000271A1 (en) | Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors | |
UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a | |
MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
MY156520A (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors | |
MX2013012588A (es) | Inhibidores de cinasa. | |
MX360030B (es) | Metodos para tratar el trastorno bipolar. | |
PH12015501980A1 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same | |
PH12014501434A1 (en) | Quinoline derivatives as pde10a enzyme inhibitors | |
TN2014000288A1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
MX2019014982A (es) | Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos. | |
MX336915B (es) | Derivados de imidazol como inhibidores de la enzima pde10a. | |
TN2013000200A1 (en) | Imidazole derivatives as pde 10a enzyme inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |